The association between socioeconomic status and tumour stage at diagnosis of ovarian cancer: A pooled analysis of 18 case-control studies by Præstegaard, Camilla et al.
The association between socioeconomic
status and tumour stage at diagnosis
of ovarian cancer: A pooled
analysis of 18 case-control studies
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Præstegaard, Camilla, Susanne K. Kjaer, Thor S.S. Nielsen, Signe
M. Jensen, Penelope M. Webb, Christina M. Nagle, Estrid Høgdall,
et al. 2016. “The Association Between Socioeconomic Status and
Tumour Stage at Diagnosis of Ovarian Cancer: A Pooled Analysis of
18 Case-Control Studies.” Cancer Epidemiology 41 (April): 71–79.
doi:10.1016/j.canep.2016.01.012.
Published Version 10.1016/j.canep.2016.01.012
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:33464191
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Open Access Policy Articles, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#OAP
The association between socioeconomic status and tumour 
stage at diagnosis of ovarian cancer: a pooled analysis of 18 
case-control studies
Camilla Præstegaarda, Susanne K. Kjaera,b, Thor S.S. Nielsena, Signe M. Jensenc, 
Penelope M. Webbd, on behalf of the Australian Ovarian Cancer Study Groupe, Christina M. 
Nagled, Estrid Høgdalla,f, Harvey A. Rischg, Mary Anne Rossingh,i, Jennifer A. Dohertyj, 
Kristine G. Wicklundh, Marc T. Goodmank,l, Francesmary Modugnom,n,o, Kirsten Moysichp, 
Roberta B. Nessq, Robert P. Edwardsr, Ellen L. Goodes, Stacey J. Winhamt, Brooke L. 
Fridleyt, Daniel W. Crameru, Kathryn L. Terryu,v, Joellen M. Schildkrautw, Andrew 
Berchuckx, Elisa V. Banderay, Lisa Paddockz,aa, Lambertus A. Kiemeneybb,cc, Leon F. 
Massugerdd, Nicolas Wentzensenee, Paul Pharoahff, Honglin Songgg, Alice S. Whittemorehh, 
Valerie McGuirehh, Weiva Siehhh, Joseph Rothsteinhh, Hoda Anton-Culverii, Argyrios 
Ziogasjj, Usha Menonkk, Simon A. Gaytherll, Susan J. Ramusll, Aleksandra Gentry-
Maharajkk, Anna H. Wull, Celeste L. Pearcell,mm, Malcolm C. Pikell,nn, Alice W. Leell, Jenny 
Chang-Claudeoo, Allan Jensena, and on behalf of the Ovarian Cancer Association 
Consortium
aVirus, Lifestyle and Genes, Danish Cancer Society Research Center, Strandboulevarden 49, 
DK-2100 Copenhagen, Denmark bDepartment of Gynecology, Rigshospitalet, Copenhagen 
University Hospital, Blegdamsvej 9, DK-2100 Copenhagen, Denmark cStatistics, Bioinformatics 
and Registry, Danish Cancer Society Research Center, Strandboulevarden 49, DK-2100 
Copenhagen, Denmark dPopulation Health Department, QIMR Berghofer Medical Research 
Institute, 300 Herston Rd, Herston, Queensland 4006 Brisbane, Australia ePeter MacCallum 
Cancer Centre, East Melbourne, Victoria, Australia fMolecular Unit, Department of Pathology, 
Herlev Hospital, Copenhagen University Hospital, Herlev Ringvej 75, DK-2730 Herlev, Denmark 
gDepartment of Chronic Disease Epidemiology, Yale School of Public Health, LEPH 413, 60 
College Street, New Haven, Connecticut 06510, USA hProgram in Epidemiology, Division of 
Public Health Sciences, Fred Hutchinson Cancer Research Center, PO Box 19024, Seattle, 
Washington 98109-1024, USA iDepartment of Epidemiology, University of Washington, PO Box 
19024, Seattle, Washington 98109-1024, USA jDepartment of Community and Family Medicine, 
Section of Biostatistics & Epidemiology, Geisel School of Medicine, Dartmouth College, 1 Medical 
Center Drive, 7927 Rubin Building, Room 884, Lebanon, Hanover, New Hampshire 03756, USA 
kCancer Prevention and Control, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai 
Medical Center, 8700 Beverly Blvd., Room 1S37, Los Angeles 90048, California, USA 
lCommunity and Population Health Research Institute, Department of Biomedical Sciences, 
Cedars-Sinai Medical Center, 8700 Beverly Blvd., Room 1S37, Los Angeles 90048, California, 
Corresponding author: Allan Jensen, Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Strandboulevarden 49, 
DK-2100 Copenhagen O, Denmark, Phone: +45 35 25 76 93, Fax: +45 35 25 77 31, allan@cancer.dk. 
Conflicts of interest: None
HHS Public Access
Author manuscript
Cancer Epidemiol. Author manuscript; available in PMC 2017 April 01.
Published in final edited form as:
Cancer Epidemiol. 2016 April ; 41: 71–79. doi:10.1016/j.canep.2016.01.012.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
USA mDepartment of Obstetrics, Gynecology and Reproductive Sciences, Division of 
Gynecologic Oncology, University of Pittsburgh School of Medicine, Magee-Womens Hospital, 
300 Halket Street (Room #2130), Pittsburgh, Pennsylvania 15222, USA nDepartment of 
Epidemiology, University of Pittsburgh Graduate School of Public Health, Magee-Womens 
Hospital, 300 Halket Street (Room #2130), Pittsburgh, Pennsylvania 15222, USA oWomens 
Cancer Research Program, Magee-Womens Research Institute and University of Pittsburgh 
Cancer Institute, Magee-Womens Hospital, 300 Halket Street (Room #2130), Pittsburgh, 
Pennsylvania 15222, USA pDepartment of Cancer Prevention and Control, Roswell Park Cancer 
Institute, Elm and Carlton Streets, Buffalo, New York 14263, USA qThe University of Texas, 
School of Public Health, P.O. Box 20186, Houston, Texas 77225, USA rDepartment of Obstetrics, 
Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Magee-
Womens Hospital, 300 Halket Street (Room #2130), Pittsburgh, Pennsylvania 15222, USA 
sDepartment of Health Science Research, Division of Epidemiology, Mayo Clinic, 200 First Street 
SW, Charlton 6, Rochester, Minnesota, USA tDepartment of Biostatistics, University of Kansas, 
5028B Robinson Building, 3901 Rainbow Blvd, Kansas City, Kansas 66160, USA uObstetrics and 
Gynecology Epidemiology Center, Brigham and Women's Hospital, 221 Longwood Avenue RFB 
368, Boston, Massachusetts 02115, USA vDepartment of Epidemiology, Harvard T. H. Chan 
School of Public Health, 221 Longwood Avenue RFB 368, Boston, Massachusetts 02115, USA 
wDepartment of Public Health Sciences, School of Medicine, University of Virginia, Box: 800717, 
Charlottesville, Virginia 22908, USA xDepartment of Obstetrics and Gynecology, Duke University 
Medical Center, 3079, Durham, North Carolina 27710, USA yCancer Prevention and Control 
Program, Rutgers Cancer Institute of New Jersey, 195 Little Albany Street, Room 5568, New 
Brunswick, New Jersey 08903, USA zNew Jersey State Cancer registry, PO Box 369, Trenton, 
New Jersey 08625-0369, USA aaRutgers School of Public Health, Piscataway, New Jersey, USA 
bbDepartment for Health Evidence, Radboud University Medical Center, PO Box 9101, 6500 HB 
Nijmegen, The Netherlands ccDepartment of Urology, Radboud University Medical Center, PO 
Box 9101, 6500 HB Nijmegen, The Netherlands ddDepartment of Obstetrics and Gynaecology, 
Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands 
eeDivision of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, 
Rockville, Maryland 20852, USA ffDepartment of Oncology, Department of Public Health and 
Primary Care, University of Cambridge, Strangeways Research laboratory, Wortscauseway, 
Cambridge, CB1 8RN, United Kingdom ggDepartment of Oncology, University of Cambridge, 
Strangeways Research Laboratory, Wortscauseway, Cambridge, CB1 8RN, United Kingdom 
hhDepartment of Health Research and Policy - Epidemiology, Stanford University School of 
Medicine, 259 Campus Drive, Stanford, California 94305-5405, USA iiDepartment of 
Epidemiology, University of California Irvine, Center for Cancer Genetics Research & Prevention, 
School of Medicine, 224 Irvine Hall, Irvine, California 92697-7550, USA jjDepartment of 
Epidemiology, University of California Irvine, 224 Irvine Hall, Irvine, California 92697-7550, USA 
kkWomen's Cancer, UCL EGA Institute for Women's Health, Maple House 1st Floor, 149 
Tottenham Court Road, London W1T 7DN, United Kingdom llDepartment of Preventive Medicine, 
Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, 
Harlyne Norris Research Tower 1450 Biggy Street, Office 2517G, Los Angeles, California 90033, 
USA mmDepartment of Epidemiology, University of Michigan School of Public Health, 1415 
Washington Heights, SPH Tower, Office #4642, Ann Arbor, Michigan 48109-2029, USA 
Præstegaard et al. Page 2
Cancer Epidemiol. Author manuscript; available in PMC 2017 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
nnDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 
East 63rd Street, New York, New York 10065, USA ooGerman Cancer Research Center, Division 
of Cancer Epidemiology, Postfach 101949, 69009 Heidelberg, Germany
Abstract
Purpose—Socioeconomic status (SES) is a known predictor of survival for several cancers and it 
has been suggested that SES differences affecting tumour stage at diagnosis may be the most 
important explanatory factor for this. However, only a limited number of studies have investigated 
SES differences in tumour stage at diagnosis of ovarian cancer. In a pooled analysis, we 
investigated whether SES as represented by level of education is predictive for advanced tumour 
stage at diagnosis of ovarian cancer, overall and by histotype. The effect of cigarette smoking and 
body mass index (BMI) on the association was also evaluated.
Methods—From 18 case-control studies, we obtained information on 10,601 women diagnosed 
with epithelial ovarian cancer. Study specific odds ratios (ORs) with corresponding 95% 
confidence intervals (CI) were obtained from logistic regression models and combined into a 
pooled odds ratio (pOR) using a random effects model.
Results—Overall, women who completed ≤high school had an increased risk of advanced 
tumour stage at diagnosis compared with women who completed >high school (pOR 1.15; 95% CI 
1.03–1.28). The risk estimates for the different histotypes of ovarian cancer resembled that 
observed for ovarian cancers combined but did not reach statistical significance. Our results were 
unchanged when we included BMI and cigarette smoking.
Conclusion—Lower level of education was associated with an increased risk of advanced 
tumour stage at diagnosis of ovarian cancer. The observed socioeconomic difference in stage at 
diagnosis of ovarian cancer calls for further studies on how to reduce this diagnostic delay.
Keywords
Epidemiology; ovarian cancer; pooled analysis; socioeconomic status; tumour stage
1. Introduction
Ovarian cancer is the 5th most common malignancy among women in developed countries 
[1]. Furthermore, it is a highly fatal disease with the worst prognosis among the 
gynaecological cancers because it is often diagnosed at an advanced tumour stage [2]. As 
tumour stage at diagnosis is among the most important prognostic factors in ovarian cancer, 
detection at an early stage is essential. However, currently there are no efficient screening 
tools for ovarian cancer and as most women only experience vague symptoms, the disease is 
often detected at an advanced stage when survival is poor. Therefore, knowledge on 
predictors for advanced stage at diagnosis of ovarian cancer is crucial to reduce the mortality 
for this disease.
Socioeconomic status (SES) is a predictor of incidence and survival of a number of diseases 
and there is evolving evidence for socioeconomic differences in cancer survival for many 
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cancer types [3;4]. However, in contrast to breast cancer, relatively few studies have 
addressed the association between SES and ovarian cancer survival and the results have been 
inconsistent. Five studies [5–9] found worse survival among women with low SES whereas 
two studies [10;11] found no association. The reasons for socioeconomic differences in 
cancer survival in general and ovarian cancer survival in particular are not well-understood 
[4]. Possible underlying causes can be separated into three groups: tumour characteristics 
(tumour stage at diagnosis and biological characteristics), health care factors (e.g., types of 
treatment received, medical expertise and utilization of screening), and patient 
characteristics (e.g., lifestyle factors and comorbidities) [4]. According to Woods et al. [4], 
SES differences in tumour stage at diagnosis is likely the most important explanation for 
differences in cancer survival for a number of cancer types; including breast- [12], 
endometrial- [13] and cervical cancer [14]. SES differences in tumour stage at diagnosis 
may be attributable to several reasons, including access to and acceptance of cancer 
screening technologies, awareness of cancer symptoms, health-seeking behaviour, access to 
health care, comorbidities, and lifestyle factors.
However, only a limited number of studies have investigated SES differences in tumour 
stage at diagnosis of ovarian cancer, and whereas the majority found no convincing evidence 
that tumour stage at diagnosis differed according to SES [15–18], one recent study showed 
that a lower level of education was associated with advanced tumour stage at diagnosis of 
ovarian cancer [8]. Many of the previous studies were limited by small sample sizes and lack 
of individual level SES data, and none of the studies investigated whether the association 
between SES and tumour stage at diagnosis differed by histotype.
Using data from 18 case-control studies included in the international Ovarian Cancer 
Association Consortium (OCAC), we performed a pooled analysis in order to evaluate the 
association between SES (represented by highest obtained level of education) and tumour 
stage at diagnosis, overall and by histotype. Furthermore, we aimed to investigate to what 
degree the association between SES and tumour stage at diagnosis was confounded by pre-
diagnosis cigarette smoking or by body mass index (BMI).
2. Materials and Methods
The Ovarian Cancer Association Consortium (OCAC) described in details elsewhere [19] is 
an international collaboration of case-control studies founded in 2005 with the original aim 
to identify genetic polymorphisms associated with ovarian carcinogenesis. More recently, 
consortial activities have included the identification of risk factors and prognostic factors for 
ovarian cancer. In the present study, we obtained data from 18 studies that provided 
information about level of education and other required variables for the study [20–37] 
(Table 1). All data were checked for internal consistencies and clarifications were provided 
by the original investigators if needed. Among women diagnosed with ovarian cancer, we 
excluded from analyses those with missing data for level of education, those with non-
epithelial ovarian tumours or epithelial tumours of low malignant potential (borderline 
ovarian tumours) and those who lacked information on age, race/ethnicity or tumour stage at 
diagnosis, leaving 10,601 women for analysis. All individual studies included in OCAC had 
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institutional review board or ethics committee approvals and all study participants provided 
informed consent.
2.1. Assessment of level of education
Information on highest attained level of education was obtained either from self-
administered questionnaires (n = 8 studies) or from in-person interviews (n = 10 studies). 
For all included OCAC studies, information on highest level of education was harmonized 
and parameterized as a dichotomous variable (≤high school versus >high school).
2.2. Statistical analysis
Of the 18 studies included for analyses, 11 (AUS, GER, HOP, MAL, MAY, NCO, NEC, 
NTH, POL, SEA and UKO) used the FIGO staging system [38], while two studies (CON 
and NJO) used SEER staging manuals [39] to stage ovarian cancer. Five studies (DOV, 
HAW, STA, UCI and USC) had information on both FIGO and SEER tumour staging. In the 
common OCAC dataset, a harmonized summary tumour stage variable was created and 
reported in the following categories: localized tumour stage, regional tumour stage or distant 
tumour stage, using the following algorithm: localized = FIGO tumour stage IA, IB, I (not 
other specified (NOS)) or SEER tumour stage 1; regional = FIGO tumour stage IC, IIA, IIB, 
IIC, II (NOS) or SEER tumour stage 2, 3, 4, 5; distant = FIGO tumour stage IIIA, IIIB, IIIC, 
III (NOS), IV or SEER tumour stage 7. For studies with information on both FIGO and 
SEER tumour staging, the harmonized summary tumour stage variable represents the more 
advanced of FIGO and SEER tumour stage. In all analyses, the harmonized OCAC tumour 
stage variable was parameterized as a dichotomous comparison of localized tumour stage or 
advanced tumour stage (regional or distant).
To compare characteristics of the included women according to tumor stage at diagnosis 
(localized stage versus advanced stage), a Pearson's chi square statistical test was used when 
data were normally distributed (histology, level of education, smoking status and race/
ethnicity) and a Wilcoxon rank sum statistical test was used when data were not normally 
distributed (age at diagnosis and BMI). We used a two-stage approach [40] to analyse the 
association between stage of ovarian cancer and level of education. First, study-specific odds 
ratios (ORs) were obtained by logistic regression models with adjustments for a priori 
selected potential confounding variables (described below). The study-specific estimates 
were then combined by random-effects inverse variance-weighted meta-analysis into a 
pooled odds ratio (pOR) with corresponding 95% confidence intervals (CIs) [41]. Statistical 
heterogeneity among studies was evaluated using the Cochran Q and I2 statistics. For all 
analyses, individual studies were included in the meta-analysis only if the following two 
requirements were met; i) five cases with complete data were available and ii) each level of 
the tumour stage variable had one or more subjects.
Two statistical models were fitted to evaluate the association of tumour stage at diagnosis of 
ovarian cancer according to level of education. Model 1 included adjustments for age at 
diagnosis (continuous variable) and race/ethnicity (non-Hispanic White, Hispanic White, 
Black, Asian or other, including unknown races). In Model 2, we additionally adjusted for 
pre-diagnosis cigarette smoking (never, former or current smoker) and BMI (determined 
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either at one or five years prior to ovarian cancer diagnosis, depending on the study) as a 
continuous variable (per 5 kg/m2). Subgroup analyses were conducted for specific histotypes 
of ovarian cancers including serous, mucinous, endometrioid and clear cell tumours. Serous 
tumours were additionally categorized as low- (grade 1) or high- (grade 2+) grade tumours. 
Finally, we also performed additional sensitivity analyses to investigate whether the 
association between level of education and tumour stage at diagnosis of ovarian cancer 
overall differed according to study continent (US versus non-US studies), race/ethnicity 
(white (non-Hispanic or Hispanic White) versus all other races/ethnicities (Black, Asian and 
other)) or study type (population-based versus hospital-/clinic-based studies). All analyses 
were conducted using the environment R, version 3.1.0. A 5% significance level was used 
for all analysis.
3. Results
Characteristics of the 18 studies that contributed data from 10,601 women with epithelial 
ovarian cancer are shown in Table 1. Eleven studies were conducted in the United States 
(US), six in Europe and one in Australia. In the studies, the number of women with ovarian 
cancer ranged from 183 to 1377. Women were 19–91 years of age at diagnosis between 
1989 and 2010. Fifteen studies were population-based and three were hospital/clinic-based. 
Almost four-fifths of the women (78.6%) had advanced tumour stage (regional or distant) at 
diagnosis of ovarian cancer.
Table 2 presents characteristics of the women included in the analysis according to tumour 
stage at diagnosis of ovarian cancer. Among women diagnosed at advanced tumour stage, 
median age at diagnosis was significantly higher (58.0 years) compared with women 
diagnosed at localized tumour stage (median age = 53.0 years). Furthermore, women 
diagnosed at advanced tumour stage of ovarian cancer were more often diagnosed with 
serous tumours, had completed ≤high school, had higher BMI, were less likely to be Asian 
and were more often a former smoker, compared with women diagnosed at a localized 
tumour stage (all p-values < 0.01).
In Table 3 are presented the pooled odds ratios for advanced tumour stage at diagnosis of 
ovarian cancer overall and within histotypes according to level of education. The table shows 
pORs based on two analytic models: Model 1 includes adjustment for age and race/ethnicity 
and Model 2 includes additional adjustment for BMI and cigarette smoking status. Women 
who completed high school or less had an increased risk of advanced tumour stage at 
diagnosis of ovarian cancer (pOR 1.15; 95% CI 1.03–1.28) (Table 3, Model 1; Figure 1). 
The risk estimates for the various histotypes generally resembled that for ovarian cancer 
overall, though none of the risk estimates reached nominal statistical significance (Table 3, 
Model 1). Additional adjustments for BMI and cigarette smoking status made virtually no 
changes to the estimated associations between level of education and tumour stage at 
diagnosis of ovarian cancer (Table 3, Model 2). Heterogeneity was not evident for any of the 
analyses included in the present paper (All p-values > 0.4 and all I2 <5%).
Lastly, we performed sensitivity analyses to investigate whether the association between 
level of education and tumour stage at diagnosis of ovarian cancer overall differed according 
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to study continent, race/ethnicity or study type. However, the direction and the magnitude of 
the associations were not markedly different from the associations obtained in the main 
analyses (Table 3). Further, the risk estimates did not differ statistically significantly 
between the US studies (pOR 1.11; 95% CI 0.97–1.28) and the non-US studies (pOR 1.22; 
95% CI 1.01–1.47), between women of white race/ethnicity (pOR 1.15; 95% CI 1.02–1.29) 
and women of other races/ethnicities (pOR 1.13; 95% CI 0.84–1.51), as well as between 
population-based studies (pOR 1.14; 95% CI 1.01–1.28) and hospital-/clinic-based studies 
(pOR 1.28; 95% CI 0.88–1.73) (all p-values for pairwise comparisons >0.05).
4. Discussion
Tumour stage is the most important prognostic factor of survival in ovarian cancer. It is 
therefore important to identify factors that predict tumour stage at diagnosis. A potential 
candidate is socioeconomic status, which has been found to be associated with tumour stage 
at diagnosis for other gynaecological cancers [12–14]. The present large study evaluated the 
association between level of education and tumour stage at diagnosis of epithelial ovarian 
cancer. Our results showed that women who completed high school or less had a modest 
(15%) increased risk of advanced tumour stage at diagnosis of ovarian cancer compared with 
women who completed more than high school. Observed risk estimates for the histotypes 
resembled those for ovarian cancer overall.
Only a few studies have investigated SES differences in tumour stage at diagnosis of ovarian 
cancer. Our results are partly in line with results from a recent Danish cohort study. Ibfelt et 
al. [8], with data of 2873 women diagnosed with ovarian cancer, observed that women with 
medium level of education (10–12 years) had a 25% increased risk of advanced tumour 
stage at diagnosis of ovarian cancer compared with women with high level of education (>12 
years). However, the authors found no association between risk of advanced tumour stage 
and short level of education (7–9 years). Other studies have found no convincing 
associations between various measures of SES and tumour stage at diagnosis of ovarian 
cancer [15–18]. For example, in the largest study to date using data from 16,228 American 
women with ovarian cancer, Morris et al. [18] found no association between a census-based 
measure of SES and tumour stage at diagnosis. An explanation for the divergent results may 
be that only our study and the study by Ibfelt et al. [8] used individual level measures of 
SES, whereas all other studies of this question have used various area-based/aggregate 
measures of SES as surrogates for individual SES. Area-based and aggregate measures of 
SES are known to be less precise (i.e., have higher risk of misclassification) than individual 
measures of SES and likely to bias relative risk toward the null in epidemiological studies 
[42]. No previous studies have examined whether or not the association between SES and 
tumour stage at diagnosis of ovarian cancer differs by histotype. We observed that the 
estimated risks for the histotypes of ovarian cancer resembled that for ovarian cancer overall. 
However, the numbers of cases for some of the histotypes were relatively small and 
additional confirmation would be warranted.
The observed association between educational level and tumour stage at diagnosis is likely 
to be explained by a complex interaction between several underlying factors, including 
patient access to regular health-care check-ups, patient awareness of cancer symptoms, 
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adequate reaction to symptoms, access, barriers and quality of healthcare, time-period to 
referral to specialist care, lifestyle factors, and comorbidities. Cancer symptom awareness 
and interpretation of symptoms is poorer among those who are less educated and those with 
lower SES [43]. Though some ovarian cancers are asymptomatic, most women experience 
vague or non-specific symptoms, which are similar to those of other common illnesses [44]. 
Therefore, it is plausible that more highly educated women could be more aware of and able 
to recognize potential symptoms compared with less educated women and may therefore be 
more likely to seek medical care earlier, which would eventually lead to a diagnosis of 
ovarian cancer in an earlier tumour stage. However, compared with cancers that are 
generally screenable or present with clear clinical signs, the potential for socioeconomic 
status to have an influence on awareness of symptoms and health-care seeking in ovarian 
cancer are likely to be rather limited. Alternatively, women that are more educated might 
respond more promptly to their apparent signs or symptoms whereas less educated women 
may be more likely to ignore, discount or deny them until mounting discomfort becomes 
substantial in advanced tumour stage disease.
Regular visits to a primary care physician and the latency from date of visit at the general 
practitioner until referral to a gynaecologist are both factors that are potentially predictive 
for tumour stage at diagnosis of ovarian cancer. As low SES is associated with less frequent 
use of primary care [45] and likely increased time to referral to a specialist, these factors 
may combine to explain the observed association between educational level and tumour 
stage at diagnosis. In the present study, 11 of 18 individual studies were conducted in the 
USA, representing 65% of the women in our study population. In contrast to Europe and 
Australia, access to health care in the USA is not uniform and a larger proportion of well-
educated American women are privately insured compared with less educated American 
women. It is plausible that women with private health insurance visit a primary care 
physician more regularly and are faster referred to a gynaecologist compared with women 
who are uninsured or covered by governmental insurance programs. Therefore, it would be 
reasonable to assume that the association between level of education and tumour stage at 
diagnosis of ovarian cancer would be more pronounced among the US studies than among 
the non-US studies. However, the results from our additional analysis stratified by study 
continent were not able to support this.
Finally, low SES is known to be associated with less unhealthy lifestyle, including factors 
such as poorer diet, less exercise, more cigarette smoking and higher BMI [46–48]. Both 
cigarette smoking and obesity accelerates carcinogenesis resulting in earlier progression and 
death, whereas obesity can blur ovarian cancer symptoms and delay diagnosis [49]. 
However, in the present study, BMI and cigarette smoking status had virtually no effect on 
the estimated associations between level of education and tumour stage at diagnosis. 
Therefore, BMI and cigarette smoking do not appear to have substantial influence on tumour 
stage difference by level of education.
A strength of the present study is the large number of ovarian cancer patients obtained by 
pooling data from 18 individual case-control studies. This collection strengthened the 
statistical power of the risk estimates and allowed us to examine associations both overall 
and separately for the various histotypes of ovarian cancer. In addition, the majority of the 
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studies were population-based designs with information on education obtained from in-
person interviews. The participating studies were not selected from among published 
studies. Therefore, our analyses included both positive and negative study-specific results, 
limiting the possibility of publication bias. The present analyses relied on individual data 
combined into a single dataset following careful central data harmonization. We considered 
differences in study design and data collection across studies and adjusted for relevant 
confounding factors across studies. However, we could not adjust for comorbidity, as this 
information was not available in our data. The degree of comorbidity is known to be 
inversely correlated with SES [50] and comorbidity may blur symptoms of cancer and may 
reduce individual resources when it comes to health care seeking. Hence, even though a 
recent cohort study showed that comorbidity only had a small impact on the differences in 
ovarian cancer stage and survival by SES [8], we cannot rule out that our results may have 
been slightly affected by unmeasured confounding from comorbidity. Furthermore, 
information on tumour stage was abstracted from hospital records or cancer registries and 
the majority of study sites performed pathology review in order to confirm histotype 
classifications. Nevertheless, not all ovarian tumours underwent systematic histopathologic 
review and therefore some degree of misclassification of subtype could have occurred. An 
additional potential limitation of the present study is that we only included one measure of 
SES - level of education - as only a limited number of OCAC studies obtained information 
on other measures such as income or marriage/cohabitation status. Even though a single 
measure of SES may show an association with the health outcome analysed, it may not 
encompass the entirety of the effect of SES on health, and inclusion of multiple measures of 
SES are always preferable [51]. Hence, by including only one measure of SES, we may only 
partly have explained the true association between SES and stage at diagnosis of ovarian 
cancer. However, level of education is considered to be a good and valid measure of SES 
with regard to health because it influences an individuals’ SES throughout life and it is 
highly associated with both income and occupation [6; 52]. Further, knowledge and skills 
obtained through education may affect cognitive functions and thereby strengthen the 
individuals’ comprehension of health messages and communication with health authorities 
[51]. Finally and perhaps most importantly, for most individuals, level of education does not 
change substantially throughout life compared with other measures of SES, including 
income and occupation, and can therefore be considered to be a robust measure of SES [51].
5. Conclusions
This large pooled analysis showed that lower educational level was associated with advanced 
tumour stage at diagnosis. BMI and cigarette smoking did not explain the association. 
Hence, in order to reduce diagnostic delays, it is important to identify which underlying 
factors (e.g., patient awareness of and response to cancer symptoms, access to healthcare 
and latency of referral to specialist care, lifestyle factors and comorbidities) that contribute 
to socioeconomic differences in tumour stage at diagnosis of ovarian cancer.
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Fig. 1. 
Risk of advanced tumour stage at diagnosis of ovarian cancer associated with level of 
education by study site and overall. Study-specific odds ratios (ORs) and 95% confidence 
intervals (CIs) were estimated using logistic regression models adjusted for age and race/
ethnicity. The pooled odds ratio (pOR) with corresponding 95% CI was estimated using a 
random effects model. Level of education was parameterized as women who completed high 
school or less versus women who completed more than high school
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Table 2
Characteristics of women diagnosed with epithelial ovarian cancer, according to tumour stage at diagnosis.
All
(n = 10,601)
Localized stage
(n = 2,270) Advanced stage
b
(n = 8,331) P-value
Age at diagnosis (years)
  Median 57.0 53.0 58.0 <0.001c
  Interquartile range 49.0–65.0 45.7–62.0 50.0–66.0
Histology
  Serous 6,066 (57.2) 501 (22.1) 5,565 (66.8) <0.001d
    Serous low-grade 479 (4.5) 98 (4.3) 381 (4.6)
    Serous high-grade 5,030 (47.4) 339 (14.9) 4,691 (56.3)
  Endometrioid 1,664 (15.7) 665 (29.3) 999 (12.0)
  Mucinous 780 (7.4) 480 (21.1) 300 (3.6)
  Clear cell 875 (8.3) 412 (18.1) 463 (5.6)
  Othera 1,216 (11.5) 212 (9.3) 1,004 (12.1)
Level of education
  ≤High school 5,190 (49.0) 1,054 (46.4) 4,136 (49.6) 0.008d
  >High school 5,411 (51.0) 1,216 (53.6) 4,195 (50.4)
BMI
Median 24.0 23.6 24.1 <0.001c
Interquartile range 21.4–28.2 20.9–28.0 21.5–28.2
Smoking status 0.02d
  Never 5,770 (54.4) 1,227 (54.1) 4,543 (54.5)
  Former 3,391 (32.0) 694 (30.6) 2,697 (32.4)
  Current 1,440 (13.6) 349 (15.4) 1,091 (13.1)
Race/ethnicity <0.001d
  Non-Hispanic White 9,129 (86.1) 1,878 (82.7) 7,251 (87.0)
  Hispanic White 306 (2.9) 62 (2.7) 244 (2.9)
  Black 265 (2.5) 53 (2.3) 212 (2.5)
  Asian 565 (5.3) 190 (8.4) 375 (4.5)
  Other 331 (3.1) 87 (3.8) 244 (2.9)
a
Includes mixed cell, undifferentiated and tumours of unknown histology
b
Includes regional or distant stage
c
The P-value was calculated using the Wilcoxon rank sum statistical test as the data were not normally distributed
d
The P-value was calculated using the Pearson’s chi square statistical test at the data were normally distributed
Numbers may not sum up to total because of missing data
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Table 3
Adjusted pooled odds ratios (pORs) and 95% confidence intervals (95% CI) for the association between level 
of education and advanced stage at diagnosis of ovarian cancer, overall and by histotype.
Model 1a Model 2b
Cases (n = 10,601) pOR (95% CI) Cases (n = 10,457) pOR (95% CI)
Overall
  >high school 5,411 1.00 5,362 1.00
  ≤high school 5,190 1.15 (1.03–1.28) 5,095 1.18 (1.05–1.32)
Serous
  >high school 3,003 1.00 2,973 1.00
  ≤high school 3,063 1.08 (0.87–1.34) 3,009 1.13 (0.90–1.41)
Serous low-grade
  >high school 143 1.00 142 1.00
  ≤high school 228 1.10 (0.51–2.35) 228 1.23 (0.49–3.12)
Serous high-grade
  >high school 2,568 1.00 2,541 1.00
  ≤high school 2,462 1.02 (0.78–1.32) 2,413 1.09 (0.83–1.43)
Endometrioid
  >high school 908 1.00 901 1.00
  ≤high school 756 1.10 (0.86–1.42) 749 1.17 (0.90–1.53)
Mucinous
  >high school 349 1.00 349 1.00
  ≤high school 271 0.97 (0.63–1.48) 266 1.09 (0.68–1.76)
Clear cell
  >high school 436 1.00 431 1.00
  ≤high school 390 1.19 (0.84–1.71) 376 1.21 (0.83–1.77)
aAdjusted for age (continuous variable) and race/ethnicity (Non-Hispanic White, Hispanic White, Black, Asian and other).
bAdjusted for the two factors in Model 1 plus adjustment for BMI (continuous variable) and cigarette smoking status (never, former or current).
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